Brought to you by 
Celgene acquires Avila Therapeutics for $350mm up front, $575mm in earn-outs
27 Jan 2012
Executive Summary
Celgene Corp. is paying $350mm up front for private drug discovery company Avila Therapeutics Inc., which could also receive a total of $575mm in earn-outs: $195mm tied to development and approval of Avila’s lead candidate AVL292, and $380mm for the clinical progress and approval of therapeutics arising from Avila’s Avilomics platform.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene acquires Avila Therapeutics for $350mm up front, $575mm in earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice